The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension

This publication has 17 references indexed in Scilit:

• Editorial Comment: Antihypertensive therapy in the era of evidence based medical practice: what to do until the facts are in
  Current Opinion in Nephrology and Hypertension, 1996
• Angiotensin receptor antagonists: focus on losartan
  The Lancet, 1995
• The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs
  Archives of internal medicine (1960), 1995
• Prevalence of Hypertension in the US Adult Population
  Hypertension, 1995
• Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects
  European Journal of Clinical Pharmacology, 1994
• Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT₁‐receptor subtype
  British Journal of Pharmacology, 1993
• Refractory Hypertension
  New England Journal of Medicine, 1992
• Cough Associated with Angiotensin Converting Enzyme Inhibition
  Journal of Cardiovascular Pharmacology, 1989
• Management of patient compliance in the treatment of hypertension. Report of the NHLBI Working Group.
  Hypertension, 1982
• RANDOMISED CLINICAL TRIAL OF STRATEGIES FOR IMPROVING MEDICATION COMPLIANCE IN PRIMARY HYPERTENSION
  The Lancet, 1975